Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Gilead to Make Antiretroviral Drug Truvada Available to 68 Developing Countries at Not-for-Profit Price

August 20, 2004

Gilead Sciences announced on Wednesday that it will offer its once-daily, fixed-dose combination antiretroviral drug Truvada through its Global Access Program to 68 developing countries at the not-for-profit price of 99 cents per patient, per day -- or $29.75 for a 30-day supply -- the AP/Forbes.com reports (AP/Forbes.com, 8/18). Earlier this month, FDA approved Truvada, which combines the company's antiretroviral drugs Viread and Emtriva. HIV/AIDS patients generally take three or more different medications at the same time (Kaiser Daily HIV/AIDS Report, 8/3). Gilead will make the drug available to all African nations and 15 other countries classified by the United Nations as "least developed," according to the AP/Forbes.com. Gilead also will offer Truvada under its Advancing Access Program to people living with HIV/AIDS in the United States who are unable to afford or obtain reimbursement for the drug (AP/Forbes.com, 8/18). "We believe that Truvada represents an important treatment option for physicians and patients around the world," Gilead President and CEO John Martin said, adding, "Access to anti-HIV medication is key to our ability to combat this global disease. Gilead is pleased to add Truvada to these existing programs, and we will continue our efforts to ensure that Truvada is available as expeditiously as possible to those individuals who can benefit from its attributes" (Gilead release, 8/18).

Back to other news for August 20, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement